

June 09, 2022

The Manager, Listing Department  
The National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
NSE Symbol : PANACEABIO

BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001  
BSE Scrip Code: 531349

**Sub.: USFDA Inspection of the Company's material Wholly-owned Subsidiary, Panacea Biotec Pharma Limited's facility at Baddi, Himachal Pradesh, India**

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we hereby inform that the United States Food and Drug Administration ("USFDA") conducted an inspection of the Company's material wholly-owned subsidiary, Panacea Biotec Pharma Limited ("PBPL") at Baddi, Himachal Pradesh, India between May 30, 2022 and June 08, 2022.

At the end of inspection, PBPL was issued a 'FDA Form 483' with eight (8) observations which are related to improvements in existing procedures and are addressable. PBPL will respond to the US FDA within the stipulated time period and work closely with US FDA to close the said observations and the closure of Warning Letter issued by the US FDA earlier on September 24, 2020.

We are committed to patient safety and quality and take quality and compliance matters seriously and stand by our commitment to fully comply with the cGMP quality standards.

We request you to kindly take this on record as per the requirements of SEBI LODR Regulations and oblige.

Thanking you,

Sincerely yours,

for **Panacea Biotec Limited**



**Vinod Goel**

Group CFO and Head Legal  
& Company Secretary

**Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)**

**Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab**

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India  
Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9015 Email: corporate@panaceabiotec.com